Karyopharm Shares Plunge After $3.7M Executive Cash Retention Program
RBC calls the drop overdone and sees it as a buying opportunity.
/ 1648 items
#XY↓
Akari Therapeutics Strengthens Balance Sheet and Prepares Phase 1 as Maxim Raises Rating to Buy
Backed by promising Trop2 ADC preclinical data, new financing, and strong ADC market momentum.
RBC Bullish on Nuvation Bio as Safusidenib Delivers Durable Responses in Glioma with New Phase 3 and Phase 2 Studies
Nuvation Bio reports strong long-term Phase 2 data for safusidenib (52% ORR, 79% PFS) and announces new Phase 3 and Phase 2 studies in IDH1-mutant glioma.
Armata Clears Key FDA Milestone, Prepares AP-SA02 Phase 3 Trial for 2026
Armata Pharmaceuticals reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding.
Rhode Island’s Most Wanted Fugitive Lived as Biotech CMO — Arrested After 21 Years on the Run
Ronald Fischer, convicted of sexual assault, evaded justice for over two decades while living under the alias Richard Graydon as CMO of Immix Biopharma.
Maxim Initiates Buy Rating on Rein Therapeutics with $4 Price Target as LTI-03 Advances
Maxim highlights reduced risk and strong progress on LTI-03 for idiopathic pulmonary fibrosis. Phase 2 RENEW trial underway with topline data expected by end of 2027.